Stocks
Funds
Screener
Sectors
Watchlists
OCUP

OCUP - Ocuphire Pharma, Inc. Stock Price, Fair Value and News

$2.83+0.02 (+0.71%)
Market Closed

32/100

OCUP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

32/100

OCUP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.07

Target 3M

$2.43

Target 6M

$2.3

OCUP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUP Price Action

Last 7 days

21.9%

Last 30 days

25.5%

Last 90 days

28.6%

Trailing 12 Months

124.6%

OCUP RSI Chart

OCUP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUP Valuation

Market Cap

195.2M

Price/Earnings (Trailing)

-2.86

Price/Sales (Trailing)

13.34

EV/EBITDA

-2.43

Price/Free Cashflow

-5.94

OCUP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.07

Target 3M

$2.43

Target 6M

$2.3

OCUP Fundamentals

OCUP Revenue

Revenue (TTM)

14.6M

OCUP Earnings

Earnings (TTM)

-68.2M

Earnings Growth (Yr)

-131.92%

Earnings Growth (Qtr)

-135.23%

OCUP Profitability

EBT Margin

-466.09%

Return on Equity

-1.1K%

Return on Assets

-188.81%

Free Cashflow Yield

-16.84%

OCUP Investor Care

Shares Dilution (1Y)

118.46%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202513.7M15.4M14.6M0
202419.0M16.4M8.4M11.0M
202334.6M29.4M24.2M19.0M
202200039.9M
202101.3M589.0K20.2M
20200000
20190000
20180000
20170000
20160000
20150000
20140000
20130000
20120000
20110000
20100000
OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.
 CEO
 WEBSITEocuphire.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

Ocuphire Pharma, Inc. Frequently Asked Questions


OCUP is the stock ticker symbol of Ocuphire Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Ocuphire Pharma, Inc. is 195.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OCUP's fair value in chart for subscribers.

The fair value guage provides a quick view whether OCUP is over valued or under valued. Whether Ocuphire Pharma, Inc. is cheap or expensive depends on the assumptions which impact Ocuphire Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUP.

As of Tue Jan 27 2026, OCUP's PE ratio (Price to Earnings) is -2.86 and Price to Sales (PS) ratio is 13.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ocuphire Pharma, Inc. has provided -0.342 (multiply by 100 for percentage) rate of return.